Overview

Pre-emptive Daratumumab Therapy of Minimal Residual Disease Reappearance or Biochemical Relapse in Multiple Myeloma

Status:
Recruiting
Trial end date:
2024-07-01
Target enrollment:
Participant gender:
Summary
PREDATOR is a study investigating a role of preemptive daratumumab therapy for preclinical relapse or progression of multiple myeloma (MM).
Phase:
Phase 2
Details
Lead Sponsor:
Polish Myeloma Consortium
Collaborators:
Bioscience, S.A.
Janssen-Cilag Ltd.
Treatments:
Antibodies, Monoclonal
Daratumumab